Year : 2011 | Volume
: 7 | Issue : 3 | Page : 270--274
Clinical outcome of patients with uterine sarcomas
Daya Nand Sharma1, Goura Kisor Rath1, Sunesh Kumar2, Lalit Kumar3, Neerja Bhatla2, Ajeet Kumar Gandhi1, Roopa Hariprasad3
1 Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India
2 Department of Gynecology and Obstetrics, All India Institute of Medical Sciences, New Delhi, India
3 Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India
Purpose: The aim of our retrospective analysis was to study and report the clinical outcome of patients with uterine sarcoma (US) treated at our center; and to share our experience with literature.
Materials and Methods: We retrieved the information regarding the patient«SQ»s demography, clinico-pathological details, treatment given, survival, and complications of all the US patients treated at our center between the years 2000-2008. The three-year overall survival (OS) was determined with respect to various prognostic factors like age, stage of disease, histopathological type, adjuvant RT etc.
Results: A total of 50 case records were retrieved for this retrospective analysis. Age ranged from 24 to 75 years with a median of 50 years. Carcinosarcoma was the commonest histopathological type (23/50 patients). FIGO stage distribution was: stage I, 27; stage II, 7; stage III, 12; stage IV, 2; and unknown stage, two patients. Forty-eight patients underwent surgery; 31 received postoperative radiation therapy (PORT) and 16 received chemotherapy therapy. Median follow-up period was 34 months (range 2-69 months). The three-year OS for the entire group of patients was 42%. Stage of the disease, histopathological type, and use of PORT were found significant prognostic factors for survival.
Conclusion: Although limited by small sample size and retrospective nature, ours is the only study on US being reported from India. Our results have demonstrated FIGO stage of the disease, histopathology and use of PORT to be the significant prognostic factor for survival. Use of chemotherapy in future trials is warranted.
Daya Nand Sharma
F-39, Ansari Nagar, New Delhi - 110 029
|How to cite this article:|
Sharma DN, Rath GK, Kumar S, Kumar L, Bhatla N, Gandhi AK, Hariprasad R. Clinical outcome of patients with uterine sarcomas.J Can Res Ther 2011;7:270-274
|How to cite this URL:|
Sharma DN, Rath GK, Kumar S, Kumar L, Bhatla N, Gandhi AK, Hariprasad R. Clinical outcome of patients with uterine sarcomas. J Can Res Ther [serial online] 2011 [cited 2020 Jul 11 ];7:270-274
Available from: http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2011;volume=7;issue=3;spage=270;epage=274;aulast=Sharma;type=0